Abstract 161P
Background
Targeted therapy and Immunotherapy have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC), particularly adenocarcinoma (AC). Among NSCLC cases, around 8-10% are ALK positive with the majority involving EML4-ALK gene variants. This study aims to explore the connection between ALK gene variants and PDL1 expression in metastatic lung AC, as there is limited data from the Indian cohort on this subject.
Methods
A retrospective analysis was conducted on data collected from 17 advanced lung AC patients with ALK gene mutations. The ALK protein variants were determined through Next-Generation Sequencing, while PDL1 expression was assessed using Immunohistochemistry with sP263 antibody. These findings were then correlated with relevant clinical parameters.
Results
The median age of the patient cohort was 46 years (range 28 to 65). Among the 17 ALK-positive, the majority had EML4-ALK gene fusions, with V1 (47.05%), V3 (35.2%), and V2 (11.7%) being the most common variants. V1 was more prevalent in females (87.5%) than males (12.5%). PDL1 negativity was observed in 64.7% of patients, while 35.2% were PDL1 positive. Specifically, PDL1 negativity was more common in the V1 variant, whereas PDL1 positivity was associated with V3. Brain metastases were more frequent in the PDL1-negative cohort (35.2%), and bone metastases and malignant pleural effusions were more common in V1 compared to V2 and V3. Table: 161P
ALK metastatic sites | Frequency |
Malignant pleural effusion | 70.5% |
Brain metastasis | 35.2% |
Bone metastasis | 35.2% |
Contralateral lung involvement | 23.5% |
Liver metastasis | 11.7% |
Conclusions
The study concludes that V1 and V3 EML4-ALK gene variants are prevalent in metastatic lung AC patients. It reveals a significant association between PDL1 expression and specific ALK variants, with V1 being more frequently associated with PDL1 negativity and V3 with PDL1 positivity. Additionally, the V1 and V3 variants were more commonly found in female patients and were associated with brain metastases. This real-world experience contributes valuable insights into treatment responses in this specific patient population.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract